ClinicalTrials.gg
CompletedNCT02806895Updated Jan 14, 2021Results posted

Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA

A Phase 2 interventional study of JZP-110 and Placebo in Obstructive Sleep Apnea and Excessive Sleepiness, sponsored by Jazz Pharmaceuticals. Completed at 1 site in Netherlands. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-01-14.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Sleep Apnea, Obstructive with a site in Netherlands — 6 open to participants now, 8 under way, none of them phase 3. Sleep Apnea, Obstructive · Netherlands.

Enrollment
15th of 16
34 · median 125
Started
2016
with 2 others
Phase 2
Only one
of the 27
Registered
11th of 27
by date
Lead sponsor
3 of 27
Jazz Pharmaceuticals

Among the 27 studies in Sleep Apnea, Obstructive with a site in Netherlands, this one is the 15th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2016, is the only one in phase 2, and was the 11th registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

6 of the 27 studies in Sleep Apnea, Obstructive with a site in Netherlands are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Sleep Apnea, Obstructive with a site in Netherlands, or all of them as a file.
02

Study summary

This trial is a randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of JZP-110 on driving performance in subjects with excessive sleepiness due to obstructive sleep apnea.

03

Conditions studied

  • Obstructive Sleep Apnea
  • Excessive Sleepiness

Keywords

  • Driving
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age 21 to 65 years inclusive
  2. Diagnosis of obstructive sleep apnea (OSA) per International Classification of Sleep Disorders (ICSD-3)
  3. 18 to \<40 kg/m2
  4. Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who are pregnant, nursing, or lactating
  2. Any other medical, behavioral, or psychiatric disorder other than OSA that is associated with excessive sleepiness
  3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to 5th Edition (DSM-5) criteria
  4. History or presence of any unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy and/or safety assessments per the judgment of the investigator
  5. History of bariatric surgery within the past year or a history of any gastric bypass procedure
  6. Presence or history of significant cardiovascular disease
  7. Unable to washout or refrain from taking any over-the-counter (OTC) or prescription medications that could affect sleep-wake function
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Once daily dosing

    Drug: Placebo

  • Active comparator
    JZP-110

    150 mg/day for first 3 days and 300 mg/day for next 4 days

    Drug: JZP-110

Interventions

  • Also known as: solriamfetol

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax)

    Subjects were instructed to drive with steady lateral position between the delineated boundaries of the slower (right) traffic lane, while maintaining a constant speed of 95 kilometers (km) per hour (hr). Deviation was measured by the vehicle's speed and lateral distance to the left lane line and was continuously recorded. Individual improvement was defined as a decrease in SDLP below the negative value of threshold; individual impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 2 hours post-dose

Secondary outcomes

  1. SDLP at 6 Hours Post-dose

    Subjects were instructed to drive with steady lateral position between the delineated boundaries of the slower (right) traffic lane, while maintaining a constant speed of 95 kilometers (km) per hour (hr). Deviation was measured by the vehicle's speed and lateral distance to the left lane line and was continuously recorded. Individual improvement was defined as a decrease in SDLP below the negative value of threshold; individual impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 6 hours post-dose

  2. Number of Subjects With Improved or Impaired Driving at a Threshold 1 Centimeter (cm) on JZP-110 Compared to Placebo 2 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 2 hours post-dose

  3. Number of Subjects With Improved or Impaired Driving at a Threshold 1.5 cm on JZP-110 Compared to Placebo 2 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 2 hours post-dose

  4. Number of Subjects With Improved or Impaired Driving at a Threshold 2.0 cm on JZP-110 Compared to Placebo 2 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 2 hours post-dose

  5. Number of Subjects With Improved or Impaired Driving at a Threshold 2.5 cm on JZP-110 Compared to Placebo 2 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 2 hours post-dose

  6. Number of Subjects With Improved or Impaired Driving at a Threshold 3.0 cm on JZP-110 Compared to Placebo 2 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 2 hours post-dose

  7. Number of Subjects With Improved or Impaired Driving at a Threshold 3.5 cm on JZP-110 Compared to Placebo 2 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 2 hours post-dose

  8. Number of Subjects With Improved or Impaired Driving at a Threshold 1.0 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 6 hours post-dose

  9. Number of Subjects With Improved or Impaired Driving at a Threshold 1.5 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 6 hours post-dose

  10. Number of Subjects With Improved or Impaired Driving at a Threshold 2.0 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 6 hours post-dose

  11. Number of Subjects With Improved or Impaired Driving at a Threshold 2.5 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 6 hours post-dose

  12. Number of Subjects With Improved or Impaired Driving at a Threshold 3.0 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 6 hours post-dose

  13. Number of Subjects With Improved or Impaired Driving at a Threshold 3.5 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

    Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

    Time frame: 6 hours post-dose

  14. Standard Deviation of Speed (SDS) at 2 Hours Post-dose

    Mean SDS was a common measure of the driver's ability to maintain a constant driving speed. Variations in driving speed were recorded and analyzed.

    Time frame: 2 hours post-dose

  15. SDS at 6 Hours Post-dose

    Mean SDS was a common measure of the driver's ability to maintain a constant driving speed. Variations in driving speed were recorded and analyzed.

    Time frame: 6 hours post-dose

  16. Number of Lapses in Driving Test at 2 Hours Post-dose

    Driving lapses (also known as lane drift, defined as deviations \> 100 cm from the mean lateral position and from the absolute lateral position for 8 seconds. Driving performance will be assessed using a standardized on-road driving test on Day 7 (Visit 4) and on Day 14 (Visit 5). A practice driving test will be done during the screening period to familiarize the subject with the vehicle and test scenario, assess if the subject can adequately operate the manual transmission vehicle, and determine if any safety concerns exist that exclude the subject from participating in the study.

    Time frame: 2 hours post-dose

  17. Number of Lapses in Driving Test at 6 Hours Post-dose

    Driving lapses (also known as lane drift, defined as deviations \> 100 cm from the mean lateral position and from the absolute lateral position for 8 seconds. Driving performance will be assessed using a standardized on-road driving test on Day 7 (Visit 4) and on Day 14 (Visit 5). A practice driving test will be done during the screening period to familiarize the subject with the vehicle and test scenario, assess if the subject can adequately operate the manual transmission vehicle, and determine if any safety concerns exist that exclude the subject from participating in the study.

    Time frame: 6 hours post-dose

  18. Psychomotor Vigilance Test (PVT) Number of Lapses at 2 Hours Post-dose

    The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Lapses were measured as (RT \> 500 msec).

    Time frame: 2 hours post-dose

  19. PVT Number of Lapses at 6 Hours Post-dose

    The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Lapses were measured as (RT \> 500 msec).

    Time frame: 6 hours post-dose

  20. PVT Mean Reaction Time at 2 Hours Post-dose

    The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Mean RT is measured in msec.

    Time frame: 2 hours post-dose

  21. PVT Mean Reaction Time at 6 Hours Post-dose

    The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Mean RT is measured In msec.

    Time frame: 6 hours post-dose

  22. PVT Inverse Reaction Time at 2 Hours Post-dose

    The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Inverse reaction time was expressed as 1/reaction time in msec.

    Time frame: 2 hours post-dose

  23. PVT Inverse Reaction Time at 6 Hours Post-dose

    The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Inverse reaction time was expressed as 1/reaction time in msec.

    Time frame: 6 hours post-dose

  24. PVT Number of Errors of Commission at 2 Hours Post-dose

    The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Errors of commission were measured as the number of responses without a stimulus or false starts with (RT \< 100 msec).

    Time frame: 2 hours post-dose

  25. PVT Number of Errors of Commission at 6 Hours Post-dose

    The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Errors of commission were measured as the number of responses without a stimulus or false starts with (RT \< 100 msec).

    Time frame: 6 hours post-dose

  26. Toronto Hospital Alert Test (THAT)

    THAT is a 10-item self-report questionnaire designed to measure perceived alertness in the preceding week. The THAT was administered at baseline and the end of each treatment period. The total score of THAT can range between 0 to 50 where the higher score indicates greater alertness.

    Time frame: Post Treatment at day 21

07

Results

Posted Jun 16, 2020

Participant flow

Participant flow — Overall Study
Milestone(Treatment Period 1) JZP-110/Placebo(Treatment Period 2) Placebo/JZP-110
Started1717
Completed1617
Not completed10

Outcome measures

PrimaryStandard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax)

Subjects were instructed to drive with steady lateral position between the delineated boundaries of the slower (right) traffic lane, while maintaining a constant speed of 95 kilometers (km) per hour (hr). Deviation was measured by the vehicle's speed and lateral distance to the left lane line and was continuously recorded. Individual improvement was defined as a decrease in SDLP below the negative value of threshold; individual impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
2 hours post-dose
Reported as:
Least squares mean · centimeter (cm)
Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax)
centimeter (cm)PlaceboJZP-110
Standard Deviation of Lateral Position (SDLP) at 2 Hours Post-dose (Approximately at Tmax)19.92 ± 0.63018.83 ± 0.627
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.0062
SecondarySDLP at 6 Hours Post-dose

Subjects were instructed to drive with steady lateral position between the delineated boundaries of the slower (right) traffic lane, while maintaining a constant speed of 95 kilometers (km) per hour (hr). Deviation was measured by the vehicle's speed and lateral distance to the left lane line and was continuously recorded. Individual improvement was defined as a decrease in SDLP below the negative value of threshold; individual impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
6 hours post-dose
Reported as:
Least squares mean · cm
SDLP at 6 Hours Post-dose
cmPlaceboJZP-110
SDLP at 6 Hours Post-dose20.04 ± 0.63219.24 ± 0.631
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.0432
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 1 Centimeter (cm) on JZP-110 Compared to Placebo 2 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 1 Centimeter (cm) on JZP-110 Compared to Placebo 2 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved15
Impaired5
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 0.0414
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 1.5 cm on JZP-110 Compared to Placebo 2 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 1.5 cm on JZP-110 Compared to Placebo 2 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved13
Impaired5
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 0.0963
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 2.0 cm on JZP-110 Compared to Placebo 2 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 2.0 cm on JZP-110 Compared to Placebo 2 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved12
Impaired5
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 0.1435
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 2.5 cm on JZP-110 Compared to Placebo 2 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 2.5 cm on JZP-110 Compared to Placebo 2 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved10
Impaired4
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 0.1796
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 3.0 cm on JZP-110 Compared to Placebo 2 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 3.0 cm on JZP-110 Compared to Placebo 2 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved8
Impaired2
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 0.1094
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 3.5 cm on JZP-110 Compared to Placebo 2 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 2 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 2 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
2 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 3.5 cm on JZP-110 Compared to Placebo 2 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved5
Impaired2
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 0.4531
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 1.0 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
6 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 1.0 cm on JZP-110 Compared to Placebo 6 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved12
Impaired7
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 0.3593
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 1.5 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
6 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 1.5 cm on JZP-110 Compared to Placebo 6 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved9
Impaired6
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 0.6072
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 2.0 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
6 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 2.0 cm on JZP-110 Compared to Placebo 6 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved8
Impaired6
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 0.7905
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 2.5 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
6 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 2.5 cm on JZP-110 Compared to Placebo 6 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved5
Impaired5
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 1.0000
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 3.0 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
6 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 3.0 cm on JZP-110 Compared to Placebo 6 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved4
Impaired4
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 1.0000
SecondaryNumber of Subjects With Improved or Impaired Driving at a Threshold 3.5 cm on JZP-110 Compared to Placebo 6 Hours Post-dose

Individual changes (solriamfetol minus placebo) in driving performance were measured by SDLP at 6 hours postdose. The Maximum McNemar symmetry analyses was used to detect an asymmetry in the distribution of the change in driving performance at 6 hours postdose. The test examined the differences in the proportions of impaired drivers and improved drivers following treatment using a generalized single McNemar test statistics were obtained at each threshold (1.0, 1.5, 2.0, 2.5, 3.0, and 3.5 cm), which was the vehicle weaving amount. Changes in SDLP exceeding 2.4 cm have been evaluated as clinically relevant. Improvement was defined as a decrease in SDLP comparing JZP-110 and placebo below the threshold and impairment was defined as an increase in SDLP above the threshold or failure to complete the driving test due to sleepiness or subjects related safety concerns.

Time frame:
6 hours post-dose
Reported as:
Count of participants · Participants
Number of Subjects With Improved or Impaired Driving at a Threshold 3.5 cm on JZP-110 Compared to Placebo 6 Hours Post-dose
ParticipantsDifference (JZP-110 -Placebo)
Improved3
Impaired4
Statistical analysis
  • Difference (JZP-110 -Placebo) · McNemar · p = 1.0000
SecondaryStandard Deviation of Speed (SDS) at 2 Hours Post-dose

Mean SDS was a common measure of the driver's ability to maintain a constant driving speed. Variations in driving speed were recorded and analyzed.

Time frame:
2 hours post-dose
Reported as:
Least squares mean · kilometers/hour (km/hr)
Standard Deviation of Speed (SDS) at 2 Hours Post-dose
kilometers/hour (km/hr)PlaceboJZP-110
Standard Deviation of Speed (SDS) at 2 Hours Post-dose2.55 ± 0.0992.62 ± 0.098
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.4116
SecondarySDS at 6 Hours Post-dose

Mean SDS was a common measure of the driver's ability to maintain a constant driving speed. Variations in driving speed were recorded and analyzed.

Time frame:
6 hours post-dose
Reported as:
Least squares mean · km/hr
SDS at 6 Hours Post-dose
km/hrPlaceboJZP-110
SDS at 6 Hours Post-dose2.84 ± 0.1002.73 ± 0.099
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.1991
SecondaryNumber of Lapses in Driving Test at 2 Hours Post-dose

Driving lapses (also known as lane drift, defined as deviations \> 100 cm from the mean lateral position and from the absolute lateral position for 8 seconds. Driving performance will be assessed using a standardized on-road driving test on Day 7 (Visit 4) and on Day 14 (Visit 5). A practice driving test will be done during the screening period to familiarize the subject with the vehicle and test scenario, assess if the subject can adequately operate the manual transmission vehicle, and determine if any safety concerns exist that exclude the subject from participating in the study.

Time frame:
2 hours post-dose
Reported as:
Least squares mean · number of lapses
Number of Lapses in Driving Test at 2 Hours Post-dose
number of lapsesPlaceboJZP-110
Number of Lapses in Driving Test at 2 Hours Post-dose2.89 ± 0.5661.76 ± 0.558
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.0806
SecondaryNumber of Lapses in Driving Test at 6 Hours Post-dose

Driving lapses (also known as lane drift, defined as deviations \> 100 cm from the mean lateral position and from the absolute lateral position for 8 seconds. Driving performance will be assessed using a standardized on-road driving test on Day 7 (Visit 4) and on Day 14 (Visit 5). A practice driving test will be done during the screening period to familiarize the subject with the vehicle and test scenario, assess if the subject can adequately operate the manual transmission vehicle, and determine if any safety concerns exist that exclude the subject from participating in the study.

Time frame:
6 hours post-dose
Reported as:
Least squares mean · number of lapses
Number of Lapses in Driving Test at 6 Hours Post-dose
number of lapsesPlaceboJZP-110
Number of Lapses in Driving Test at 6 Hours Post-dose2.07 ± 0.5732.12 ± 0.573
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.9391
SecondaryPsychomotor Vigilance Test (PVT) Number of Lapses at 2 Hours Post-dose

The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Lapses were measured as (RT \> 500 msec).

Time frame:
2 hours post-dose
Reported as:
Least squares mean · lapses
Psychomotor Vigilance Test (PVT) Number of Lapses at 2 Hours Post-dose
lapsesPlaceboJZP-110
Psychomotor Vigilance Test (PVT) Number of Lapses at 2 Hours Post-dose6.37 ± 2.1112.71 ± 2.077
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.2116
SecondaryPVT Number of Lapses at 6 Hours Post-dose

The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Lapses were measured as (RT \> 500 msec).

Time frame:
6 hours post-dose
Reported as:
Least squares mean · lapses
PVT Number of Lapses at 6 Hours Post-dose
lapsesPlaceboJZP-110
PVT Number of Lapses at 6 Hours Post-dose7.73 ± 2.1113.60 ± 2.086
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.1604
SecondaryPVT Mean Reaction Time at 2 Hours Post-dose

The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Mean RT is measured in msec.

Time frame:
2 hours post-dose
Reported as:
Least squares mean · msec
PVT Mean Reaction Time at 2 Hours Post-dose
msecPlaceboJZP-110
PVT Mean Reaction Time at 2 Hours Post-dose318.66 ± 19.307286.55 ± 19.004
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.2144
SecondaryPVT Mean Reaction Time at 6 Hours Post-dose

The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Mean RT is measured In msec.

Time frame:
6 hours post-dose
Reported as:
Mean · msec
PVT Mean Reaction Time at 6 Hours Post-dose
msecPlaceboJZP-110
PVT Mean Reaction Time at 6 Hours Post-dose341.37 ± 19.307286.88 ± 19.188
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.0387
SecondaryPVT Inverse Reaction Time at 2 Hours Post-dose

The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Inverse reaction time was expressed as 1/reaction time in msec.

Time frame:
2 hours post-dose
Reported as:
Least squares mean · (1/RT(ms))
PVT Inverse Reaction Time at 2 Hours Post-dose
(1/RT(ms))PlaceboJZP-110
PVT Inverse Reaction Time at 2 Hours Post-dose3.59 ± 0.1113.69 ± 0.110
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.3426
SecondaryPVT Inverse Reaction Time at 6 Hours Post-dose

The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Inverse reaction time was expressed as 1/reaction time in msec.

Time frame:
6 hours post-dose
Reported as:
Least squares mean · (1/RT(ms))
PVT Inverse Reaction Time at 6 Hours Post-dose
(1/RT(ms))PlaceboJZP-110
PVT Inverse Reaction Time at 6 Hours Post-dose3.59 ± 0.1113.75 ± 0.110
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.1531
SecondaryPVT Number of Errors of Commission at 2 Hours Post-dose

The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Errors of commission were measured as the number of responses without a stimulus or false starts with (RT \< 100 msec).

Time frame:
2 hours post-dose
Reported as:
Least squares mean · lapses
PVT Number of Errors of Commission at 2 Hours Post-dose
lapsesPlaceboJZP-110
PVT Number of Errors of Commission at 2 Hours Post-dose2.40 ± 0.7411.82 ± 0.730
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.5603
SecondaryPVT Number of Errors of Commission at 6 Hours Post-dose

The PVT was administered at screening for practice only, and at pre-dose and within 30 minutes before each driving test on Days 7 and 14 (Visits 4 and 5, respectively). The test was administered over 10 minutes with visual stimuli appearing randomly at variable intervals of 2 to 10 seconds. Subjects were instructed to respond to the appearance of a visual stimulus on a computer screen by pushing a response button as quickly as possible. Errors of commission were measured as the number of responses without a stimulus or false starts with (RT \< 100 msec).

Time frame:
6 hours post-dose
Reported as:
Least squares mean · lapses
PVT Number of Errors of Commission at 6 Hours Post-dose
lapsesPlaceboJZP-110
PVT Number of Errors of Commission at 6 Hours Post-dose2.46 ± 0.7411.76 ± 0.740
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.4851
SecondaryToronto Hospital Alert Test (THAT)

THAT is a 10-item self-report questionnaire designed to measure perceived alertness in the preceding week. The THAT was administered at baseline and the end of each treatment period. The total score of THAT can range between 0 to 50 where the higher score indicates greater alertness.

Time frame:
Post Treatment at day 21
Reported as:
Least squares mean · score on a scale
Toronto Hospital Alert Test (THAT)
score on a scalePlaceboJZP-110
Toronto Hospital Alert Test (THAT)23.94 ± 1.18027.52 ± 1.162
Statistical analysis
  • Placebo vs JZP-110 · ANOVA · p = 0.0241

Adverse events

Collected over Adverse events were reported from the time written informed consent was obtained until the final study visit or early termination, up to 21 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/33 (0%)0/33 (0%)8/33 (24.2%)
JZP-1100/34 (0%)0/34 (0%)15/34 (44.1%)
Most frequent other events
Most frequent other events
EventPlaceboJZP-110
HeadacheNervous system disorders4/334/34
NauseaGastrointestinal disorders2/334/34
InsomniaPsychiatric disorders0/334/34
DizzinessNervous system disorders2/333/34

Baseline characteristics

Age, Continuous
Age, Continuous(years)JZP-110/PlaceboPlacebo/JZP-110Total
Mean51.0 ± 11.8552.2 ± 15.0851.6 ± 12.30
Sex: Female, Male
Sex: Female, Male(Participants)JZP-110/PlaceboPlacebo/JZP-110Total
Female134
Male161430
Race (NIH/OMB)
Race (NIH/OMB)(Participants)JZP-110/PlaceboPlacebo/JZP-110Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White171734
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)JZP-110/PlaceboPlacebo/JZP-110Total
Netherlands171734
08

Study locations

1 site
  • Maastricht University
    Maastricht, Limburg 6229, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in May 2019, 34 months.

Results were first posted in Jun 2020, 1 year after primary completion.

Of 47 phase 2 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 46. This study's 34 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2016
First posted
Jun 21, 2016
StartActual
Jul 5, 2016
Primary completionActual
May 28, 2019
CompletionActual
May 28, 2019
Results first posted
Jun 16, 2020
Last update
Jan 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02806895
Responsible party
Sponsor
First posted
Jun 21, 2016
Start date
Jul 5, 2016
Primary completion
May 28, 2019
Completion
May 28, 2019
Results posted
Jun 16, 2020
Last update
Jan 14, 2021

Study contacts

Grace Wang, MD
study director · Jazz Pharmaceuticals
Jan Ramaekers, PhD
principal investigator · Maastricht University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion